(Autologous Human Mesenchymal Stem Cells(University of Miami)) - 在研适应症：心肌梗塞，左心室功能不全_专利_临床

概要

基本信息

药物类型

间充质干细胞疗法

别名-

靶点-

作用机制-

治疗领域

心血管疾病

在研适应症

心肌梗塞左心室功能不全

非在研适应症-

原研机构

University of Miami

在研机构

University of Miami

非在研机构-

最高研发阶段临床2期

首次获批日期-

最高研发阶段(中国)-

特殊审评-

关联

9

项与 Autologous Human Mesenchymal Stem Cells(University of Miami) 相关的临床试验

NCT02503280 / Withdrawn临床1/2期IIT

A Phase I/II, Randomized, Placebo-Controlled Study of the Safety and Efficacy of Transendocardial Injection of Autologous Human Cells (Mesenchymal or the Combination of MSC and Cardiac Stem Cells) in Patients With Chronic Ischemic Left Ventricular Dysfunction and Heart Failure Secondary to Myocardial Infarction.

Before initiating the full randomized study, a Pilot Safety Phase will be performed. In this phase the composition of cells administered via the Biosense Webster MyoStar NOGA Injection Catheter System will be tested. The randomized portion of the study will be conducted after a full review of the safety data from the pilot Phase by the Data safety monitoring board.
Following the Pilot Phase of five (5) Fifty (50) patients scheduled to undergo cardiac catheterization and meeting all inclusion/exclusion criteria will be evaluated at baseline.
Patients will be randomized in a 2:2:1 ratio to one of three Treatment Strategies.

开始日期2025-03-01

申办/合作机构

University of Miami

IRCT20160809029275N2 / Recruiting临床2期

Safety and immuno-modulation evaluation of treatment with intravenous and spinal cord injections of of autologous mesenchymal stem cells in patients with amyotrophic lateral sclerosis (ALS).

开始日期2020-06-21

申办/合作机构

Mashhad University of Medical Sciences

JPRN-JMA-IIA00332 / Suspended临床2期

Intravenous infusion of autologous mesenchymal stem cells from bone marrow for dementia patients: open-label trial

开始日期2020-03-01

申办/合作机构-

100 项与 Autologous Human Mesenchymal Stem Cells(University of Miami) 相关的临床结果

登录后查看更多信息

100 项与 Autologous Human Mesenchymal Stem Cells(University of Miami) 相关的转化医学

登录后查看更多信息

100 项与 Autologous Human Mesenchymal Stem Cells(University of Miami) 相关的专利（医药）

登录后查看更多信息

5

项与 Autologous Human Mesenchymal Stem Cells(University of Miami) 相关的文献（医药）

2023-01-01·Multiple sclerosis (Houndmills, Basingstoke, England)

Evaluation of neurotrophic factor secreting mesenchymal stem cells in progressive multiple sclerosis

Article

作者: Lock, Christoper ; Aricha, Revital ; Mehra, Munish ; Chitnis, Tanuja ; Levy, Yossef ; Lublin, Fred D ; Lindborg, Stacy ; Pelletier, Daniel ; Gothelf, Yael ; Motamed Khorasani, Afsaneh ; Lebovits, Chaim ; Kern, Ralph ; Cohen, Jeffrey A

Background::

Autologous mesenchymal stem cell neurotrophic factor–secreting cells (NurOwn®) have the potential to modify underlying disease mechanisms in progressive multiple sclerosis (PMS).

Objective::

This open-label phase II study was conducted to evaluate safety/efficacy of three intrathecal cell treatments.

Methods::

Eighteen participants with non-relapsing PMS were treated. The primary endpoint was safety. Secondary endpoints included: cerebrospinal fluid (CSF) biomarkers; timed 25-foot walk speed, nine-hole peg test (9-HPT), low-contrast letter acuity, symbol digit modalities test, and 12-item multiple sclerosis (MS) walking scale. Seventeen participants received all treatments.

Results::

No deaths/adverse events related to worsening of MS, clinical/magnetic resonance imaging (MRI) evidence of disease activation, and clinically significant changes in safety lab results were reported. Two participants developed symptoms of low back and leg pain, consistent with a diagnosis of arachnoiditis, occurring in one of three intrathecal treatments in both participants. Nineteen percent of treated participants achieved pre-specified ⩾ 25% improvements in timed 25-foot walk speed/nine-HPT at 28 weeks compared to baseline, along with consistent efficacy signals for pre-specified response criteria across other secondary efficacy outcomes. CSF neuroprotective factors increased, and inflammatory biomarkers decreased after treatment, consistent with the proposed mechanism of action.

Conclusion::

Based on these encouraging preliminary findings, further confirmation in a randomized study is warranted.

2019-02-01·CNS neuroscience & therapeutics2区 · 医学

Available and future treatments for atypical parkinsonism. A systematic review

2区 · 医学

ReviewOA

作者: Moretti, Davide Vito

Abstract:

Aims:

Success in treating patients with atypical parkinsonian syndromes, namely progressive supranuclear palsy (PSP), cortico‐basal degeneration (CBD), multiple system atrophy (MSA), Parkinson's disease with dementia (PDD), and Lewy body dementia with (LBD), remains exceedingly low. The present work overviews the most influential research literature collected on MEDLINE, ISI Web of Science, Cochrane Library, and Scopus for available treatment in atypical parkinsonisms without time restriction.

Discussion:

Transdermal rotigotine, autologous mesenchymal stem cells, tideglusib, and coenzyme Q10 along with donepezil, rivastigmine, memantine, and the deep brain stimulation have shown some benefits in alleviating symptoms in APS. Moreover, many new clinical trials are ongoing testing microtubule stabilizer, antitau monoclonal antibody, tau acetylation inhibition, cell replacement, selective serotonin reuptake inhibitor, active immunization, inhibition of toxic α‐synuclein oligomers formation, and inhibition of microglia.

Conclusion:

A detailed knowledge of the pathological mechanism underlying the disorders is needed, and disease‐modifying therapies are required to offer better therapeutic options to physician and caregivers of APS patients.

2017-09-01·Advances in medical sciences4区 · 医学

Treatment of refractory epilepsy patients with autologous mesenchymal stem cells reduces seizure frequency: An open label study

4区 · 医学

Article

作者: Potapnev, Michael ; Misyuk, Nikolai ; Goncharova, Natalia ; Slobina, Elena ; Makhrov, Michael ; Shamruk, Irina ; Dakukina, Tatiana ; Ihnatsenko, Svetlana ; Shakhbazau, Antos ; Marchuk, Sergei ; Korolevich, Pavel ; Hlebokazov, Fedor ; Kosmacheva, Svetlana ; Dakukina, Victoria

PURPOSE:

Existing anti-epileptic drugs (AED) have limited efficiency in many patients, necessitating the search for alternative approaches such as stem cell therapy. We report the use of autologous patient-derived mesenchymal stem cells (MSC) as a therapeutic agent in symptomatic drug-resistant epilepsy in a Phase I open label clinical trial (registered as NCT02497443).

PATIENTS AND METHODS:

The patients received either standard treatment with AED (control group), or AED supplemented with single intravenous administration of undifferentiated autologous MSC (target dose of 1×10⁶cells/kg), followed by a single intrathecal injection of neurally induced autologous MSC (target dose of 0.1×10⁶cells/kg).

RESULTS:

MSC injections were well tolerated and did not cause any severe adverse effects. Seizure frequency was designated as the main outcome and evaluated at 1 year time point. 3 out of 10 patients in MSC therapy group achieved remission (no seizures for one year and more), and 5 additional patients became responders to AEDs, while only 2 out of 12 patients became responders in control group (difference significant, P=0.0135).

CONCLUSIONS:

MSC possess unique immunomodulatory properties and are a safe and promising candidate for cell therapy in AED resistant epilepsy patients.

100 项与 Autologous Human Mesenchymal Stem Cells(University of Miami) 相关的药物交易

登录后查看更多信息

研发状态

10 条进展最快的记录,

登录

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
心肌梗塞	临床2期	-	University of Miami	-
左心室功能不全	临床2期	-	University of Miami	-

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT00768066 (CTgov)	临床1/2期	左心室功能不全 \| 心肌梗塞 \| 心脏衰竭	65	Autologous human mesenchymal cells (hMSCs) (200 Million Autologous Human Mesenchymal Stem Cells (hMSCs))	鹹齋製鹽觸構遞壓範鏇(齋糧艱構鑰膚觸繭窪構) = 繭廠夢鹽鑰顧鹹窪膚築鹹窪衊顧網鬱窪鬱衊獵 (繭網顧壓簾廠憲醖顧餘, 窪顧襯築鏇鑰顧築顧鬱 ~ 鬱淵積繭構簾醖鏇築衊) 更多	-	2015-12-14
				Autologous human bone marrow cells (hBMCs) (200 Million Autologous Human Bone Marrow Cells (hBMCs))	鹹齋製鹽觸構遞壓範鏇(齋糧艱構鑰膚觸繭窪構) = 鹽觸鬱積鏇簾範遞顧構鹹窪衊顧網鬱窪鬱衊獵 (繭網顧壓簾廠憲醖顧餘, 網壓憲範顧簾齋壓膚壓 ~ 製範艱鹽壓窪蓋範憲艱) 更多
NCT01087996 (CTgov)	临床1/2期	造血干细胞移植 \| 左心室功能不全 \| 心肌梗塞	31	Allo-hMSCs (Allo-hMSCs)	夢築遞醖鏇憲鹹齋憲襯(夢積獵鏇選選構繭夢淵) = 鏇壓糧壓獵鏇餘艱壓製鬱選襯製膚壓構鹽顧選 (鏇艱淵窪簾鏇衊醖齋積, 獵鬱鏇廠齋壓齋餘夢顧 ~ 鬱範鹽構膚選繭齋選襯) 更多	-	2015-05-27
				Auto-hMSCs (Auto-hMSCs)	夢築遞醖鏇憲鹹齋憲襯(夢積獵鏇選選構繭夢淵) = 築範壓衊醖簾憲壓餘醖鬱選襯製膚壓構鹽顧選 (鏇艱淵窪簾鏇衊醖齋積, 醖鹹淵糧艱淵鹽齋構鹽 ~ 糧鹹顧夢廠簾糧齋積廠) 更多